Last reviewed · How we verify
Eszopiclone 2 mg- Non-elderly
Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.
Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep. Used for Insomnia (sleep initiation and maintenance) in non-elderly adults.
At a glance
| Generic name | Eszopiclone 2 mg- Non-elderly |
|---|---|
| Also known as | SEP-190 |
| Sponsor | Eisai Co., Ltd. |
| Drug class | Nonbenzodiazepine hypnotic (Z-drug) |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. By enhancing the effect of the inhibitory neurotransmitter GABA, it increases neuronal hyperpolarization and reduces neuronal excitability, leading to sedation and sleep initiation. It is selective for GABA-A receptors over other CNS targets, which contributes to its favorable safety profile compared to older benzodiazepines.
Approved indications
- Insomnia (sleep initiation and maintenance) in non-elderly adults
Common side effects
- Headache
- Dizziness
- Somnolence/Drowsiness
- Unpleasant taste
- Anxiety
- Dry mouth
Key clinical trials
- Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
- Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
- A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |